Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÖzdilli, K.
dc.contributor.authorSavran O?uz, F.
dc.contributor.authorAnak, S.
dc.contributor.authorÖ?ret, Y.
dc.contributor.authorÇiftçi, H.Ş.
dc.contributor.authorO?uz, R.
dc.contributor.authorCarin, M.
dc.date.accessioned2022-01-29T16:52:27Z
dc.date.available2022-01-29T16:52:27Z
dc.date.issued2021
dc.identifier.issn13059319
dc.identifier.urihttps://doi.org/10.4274/BMJ.galenos.2021.41636
dc.identifier.urihttp://hdl.handle.net/11446/4475
dc.description.abstractObjective: Hematopoietic stem cell transplantation (HSCT) is an important therapy for hematological diseases. One of the most significant complications of HSCT is graft versus host disease (GVHD), and major histocompatibility complex (MHC) is well known to affect GVHD and graft rejection. This study aimed to examine the effect of human leukocyte antigens (HLA) on the incidence of GVHD development in patients with leukemia. Methods: The association between HLA and GVHD formation was evaluated in 57 patients with HSCT with HLA-identical sibling donors, of whom 37 were boys and 20 were girls with a mean age of 10.11 years. All patients were diagnosed with leukemia; acute myeloid leukemia (n=33), acute lymphoblastic leukemia (n=15), and chronic myeloid leukemia (n=9). Transplantation pairs were worked for HLA-A, -B, -C, and -DRB1 alleles. Class I HLA antigens were investigated using Terasaki microlymphocytotoxicity, whereas class II HLA alleles with polymerase chain reaction - sequence-specific amplification method. Results: The frequency of developing GVHD in patients with HSCT was found to be 17.5% (n=10). HLA-DRB1?04 allelic frequency [p=0.024, odds ratio (OR): 4.87] was found to be higher in patients who developed GVHD. However, the HLA-DRB1?11 allelic frequency (p=0.031, OR: 0.12) was lower in patients who developed GVHD compared to patients who did not develop GVHD. Furthermore, HLA-B38 (p=0.002) and HLA-B41 (p=0.002) antigens were found only in patients who developed GVHD. The frequencies of the HLA-A26 allele (p=0.12) and the HLADRB1?11 allele (p=0.037, OR: 4.0) were higher in patients with relapse after HSCT; however, the frequencies of the HLA-A2 allele (p=0.033, OR: 0.19) was lower in patients who relapsed after HSCT. Conclusion: This study assessed the relationship of HLA class with GVHD, relapse, and survival in children after HSCT in pediatric patients with leukemia. © 2021 Galenos Publishing House. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherGalenos Publishing Houseen_US
dc.identifier.doi10.4274/BMJ.galenos.2021.41636
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGVHD; HLA; HSCT; Leukemiaen_US
dc.subjectbusulfanen_US
dc.subjectcyclophosphamideen_US
dc.subjectetoposideen_US
dc.subjectHLA A antigenen_US
dc.subjectHLA antigenen_US
dc.subjectHLA B antigenen_US
dc.subjectHLA B38 antigenen_US
dc.subjectHLA C antigenen_US
dc.subjectHLA DRB1 antigenen_US
dc.subjectacute lymphoblastic leukemiaen_US
dc.subjectacute myeloid leukemiaen_US
dc.subjectalleleen_US
dc.subjectArticleen_US
dc.subjectcancer survivalen_US
dc.subjectcancer transplantationen_US
dc.subjectchilden_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjectcontrolled studyen_US
dc.subjectdisease associationen_US
dc.subjectfemaleen_US
dc.subjectgene frequencyen_US
dc.subjectgraft survivalen_US
dc.subjectgraft versus host reactionen_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjecthumanen_US
dc.subjecthuman cellen_US
dc.subjecthuman tissueen_US
dc.subjectlymphocytotoxicityen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectpediatric patienten_US
dc.subjectpolymerase chain reactionen_US
dc.subjectschool childen_US
dc.subjectsibling donoren_US
dc.subjectsurvival rateen_US
dc.titleThe Influence of Human Leukocyte Antigens in Graft Versus Host Disease and Survival After Hematopoiet ic Stem Cell Transplantation in Pediatric Patients with Leukemiaen_US
dc.typearticleen_US
dc.relation.journalMedical Journal of Bakirkoyen_US
dc.departmentDBÜen_US
dc.identifier.issue4en_US
dc.identifier.volume17en_US
dc.identifier.startpage280en_US
dc.identifier.endpage285en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempÖzdilli, K., Medipol University, Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey, Istanbul University, Istanbul Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey; Savran O?uz, F., Istanbul University, Istanbul Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey; Anak, S., Medipol University, Faculty of Medicine, Department of Pediatric Hematology, Istanbul, Turkey; Ö?ret, Y., Istanbul University, Istanbul Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey; Çiftçi, H.Ş., Istanbul University, Istanbul Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey; O?uz, R., Istanbul Demiro?lu Bilim University, Gayrettepe Florence Nightingale Hospital, Tissue Typing and Immunogenetic Laboratory, Istanbul, Turkey; Carin, M., Istinye University, Tissue Typing and Immunogenetic Laboratory, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster